Department of Public Health, University of Cagliari, Cagliari, Italy.
BMC Psychiatry. 2011 Oct 10;11:164. doi: 10.1186/1471-244X-11-164.
To determine the use of antidepressants (ADs) in people with sub-threshold depression (SD); the lifetime prevalence of mania and hypomania in SD and the link between ADs use, bipolarity and anxiety disorders in SD.
community survey.
samples randomly drawn, after stratification from the adult population of municipal records.
4999 people from seven areas within six Italian regions. Tools: Questionnaire on psychotropic drug consumption, prescription; Structured Clinical Interview NP for DSM-IV modified (ANTAS); Hamilton Depression Rating Scale (HAM-D); Mood Disorder Questionnaire (MDQ); Short Form Health Survey (SF-12). SD definition: HAM-D > 10 without lifetime diagnosis of Depressive Episode (DE).
SD point prevalence is 5.0%. The lifetime prevalence of mania and hypomania episodes in SD is 7.3%. Benzodiazepines (BDZ) consumption in SD is 24.1%, followed by ADs (19.7%). In SD, positive for MDQ and comorbidity with Panic Disorder (PD) or Generalized Anxiety Disorders (GAD) are associated with ADs use, whereas the association between a positive MDQ and ADs use, without a diagnosis of PD or GAD, is not significant. Only in people with DE the well-being (SF-12) is higher among those using first-line antidepressants compared to those not using any medication. In people with SD no significant differences were found in terms of SF-12 score according to drug use.
This study suggests caution in prescribing ADs to people with SD. In people with concomitant anxiety disorders and SD, it should be mandatory to perform a well-designed assessment and evaluate the presence of previous manic or hypomanic symptoms prior to prescribing ADs.
确定亚阈抑郁(SD)人群中抗抑郁药(ADs)的使用情况;SD 中躁狂和轻躁狂的终身患病率以及 SD 中 ADs 使用、双相情感障碍和焦虑障碍之间的联系。
社区调查。
从市政记录的成年人群中分层后随机抽取样本。
来自意大利六个地区七个地区的 4999 人。工具:精神药物消费问卷、处方;DSM-IV 修正版的结构临床访谈 NP(ANTAS);汉密尔顿抑郁评定量表(HAM-D);心境障碍问卷(MDQ);简短健康调查(SF-12)。SD 定义:HAM-D>10 且无抑郁发作(DE)的终身诊断。
SD 点患病率为 5.0%。SD 中躁狂和轻躁狂发作的终身患病率为 7.3%。SD 中苯二氮䓬(BDZ)的消费率为 24.1%,其次是 ADs(19.7%)。在 SD 中,MDQ 阳性和伴惊恐障碍(PD)或广泛性焦虑障碍(GAD)的共病与 ADs 使用相关,而 MDQ 阳性与 ADs 使用相关但无 PD 或 GAD 诊断则不显著。只有在 DE 人群中,使用一线抗抑郁药的人比不使用任何药物的人幸福感(SF-12)更高。在 SD 人群中,根据药物使用情况,SF-12 评分无显著差异。
本研究表明在 SD 人群中开具 ADs 时应谨慎。在伴有焦虑障碍和 SD 的人群中,在开具 ADs 之前,必须进行精心设计的评估并评估先前出现的躁狂或轻躁狂症状。